CDK4/6-IN-14 是一种有效且高度选择性的 CDK4 和 CDK6(CDK)抑制剂,其 IC50 分别为 10 nM 和 16 nM,对 CDK1、2、7 和 9 的选择性超过 60 倍,并在其他 205 种激酶中表现出高选择性。
产品编号: MS-I62718 CAS No.: 2699091-15-9 分子式: C24H27ClFN7O 分子量: 483.97
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

CDK4/6-IN-14 是一种有效且高度选择性的 CDK4 和 CDK6(CDK)抑制剂,其 IC50 分别为 10 nM 和 16 nM,对 CDK1、2、7 和 9 的选择性超过 60 倍,并在其他 205 种激酶中表现出高选择性。

生物实验数据

生物活性 CDK4/6-IN-14 is a potent and highly selective inhibitor of CDK4 and CDK6 (CDK) with IC50 values of 10 nM and 16 nM, respectively, exhibiting over 60-fold selectivity against CDK1, 2, 7, and 9 and high selectivity across 205 other kinases.
IC50 & Target CDK6:16 nM, CDK2:1045 nM, CDK1:>10000 nM, CDK9:2664 nM, CDK7:2595 nM, CDK4:10 nM
体外研究
(In Vitro)

CDK4/6-IN-14 (compound 42; 1-6 μM; 5 days) exhibits potent inhibitory activity against the proliferation of breast cancer MCF-7, T47D, and ZR-75-1 cell lines. CDK4/6-IN-14 significantly inhibits growth and clone formation of MCF-7 and T47D cells.
CDK4/6-IN-14 (compound 42; 1-6 μM) arrests the cell cycle at the G1 phase of MCF-7 and T47D cells in the dose-dependent manner.
CDK4/6-IN-14 (compound 42; 1-6 μM; 24 hours) significantly inhibits the phosphorylation of retinoblastoma (RB), while the expression of RB protein was almost unchanged. In addition, CDK4/6-IN-14 exhibits a concentration-dependent effect to decrease the level of c-MYC and cyclin D1.

Cell Cytotoxicity Assay

Cell Line: MCF-7 and T47D cells
Concentration: 1 μM, 2 μM, 4 μM (T47D cells); 1.5 μM, 3 μM, 6 μM (MCF-7 cells)
Incubation Time: 5 days
Result: Significantly inhibited growth and clone formation of MCF-7 and T47D cells.

Western Blot Analysis

Cell Line: MCF-7 and T47D cells
Concentration: 1 μM, 2 μM, 4 μM (T47D cells); 1.5 μM, 3 μM, 6 μM (MCF-7 cells)
Incubation Time: 24 hours
Result: Significantly inhibited the phosphorylation of RB.
体内研究
(In Vivo)

CDK4/6-IN-14 (compound 42; 100-150 mg/kg; p.o; once a day; for 23 days) significantly inhibits tumor growth of the MCF-7 xenograft model.
CDK4/6-IN-14 (compound 42) exhibits a suitable t1/2 of intravenous and oral administration (2.62 and 3.59 h, respectively). Moreover, the oral bioavailability of CDK4/6-IN-14 is 43%.
Pharmacokinetic Parameters of CDK4/6-IN-14 (Compound 42) in Sprague–Dawley Rats.

admin. Cmax (ng/mL) AUC0-∞ (h × ng/mL) MRT0-∞ (h) Tmax (h) t1/2 (h) F (%)
IV 290.52 372.56 3.50 0.033 2.62
PO 144.11 1612.18 9.11 6 3.59 43
Dose: i.v. at 1 mg/kg; p.o. at 10 mg/kg

Animal Model: BALB/c nude mice bearing MCF-7 cells
Dosage: 100 mg/kg, 150 mg/kg
Administration: Orally administertion; once a day; for 23 days
Result: Significantly inhibited tumor growth of the MCF-7 xenograft model.

化学信息

分子量 483.97
分子式 C24H27ClFN7O
CAS No. 2699091-15-9

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础